Prediction of Type 2 Diabetes by Hemoglobin A1c in Two Community-Based Cohorts

OBJECTIVEHemoglobin A(1c) (HbA(1c)) can be used to assess type 2 diabetes (T2D) risk. We asked whether HbA(1c) was associated with T2D risk in four scenarios of clinical information availability: 1) HbA(1c) alone, 2) fasting laboratory tests, 3) clinic data, and 4) fasting laboratory tests and clinic data.RESEARCH DESIGN AND METHODSWe studied a prospective cohort of white (N = 11,244) and black (N = 2,294) middle-aged participants without diabetes in the Framingham Heart Study and Atherosclerosis Risk in Communities study. Association of HbA(1c) with incident T2D (defined by medication use or fasting glucose [FG] 126 mg/dL) was evaluated in regression models adjusted for 1) age and sex (demographics); 2) demographics, FG, HDL, and triglycerides; 3) demographics, BMI, blood pressure, and T2D family history; or 4) all preceding covariates. We combined results from cohort and race analyses by random-effects meta-analyses. Subsidiary analyses tested the association of HbA(1c) with developing T2D within 8 years or only after 8 years.RESULTSOver 20 years, 3,315 individuals developed T2D. With adjustment for demographics, the odds of T2D increased fourfold for each percentage-unit increase in HbA(1c). The odds ratio (OR) was 4.00 (95% CI 3.14, 5.10) for blacks and 4.73 (3.10, 7.21) for whites, resulting in a combined OR of 4.50 (3.35, 6.03). After adjustment for fasting laboratory tests and clinic data, the combined OR was 2.68 (2.15, 3.34) over 20 years, 5.79 (2.51, 13.36) within 8 years, and 2.23 (1.94, 2.57) after 8 years.CONCLUSIONSHbA(1c) predicts T2D in different common scenarios and is useful for identifying individuals with elevated T2D risk in both the short- and long-term.